The Impact of Gonadotropin-releasing Hormone Agonist Combined with Lauromacrogol on Ovarian Reserve Function and Pain Scores in Patients with Ovarian Endometriotic Cysts

Abstract Objectives: To evaluate the efficacy of gonadotropin-releasing hormone agonist (GnRHa) combined with lauromacrogol sclerotherapy in preserving ovarian reserve and reducing pain in patients with ovarian endometriotic cysts (OECs). Materials and Methods: Eighty OEC patients (Oct 2020–Oct 2024) were randomized into two groups ( n = 40 each). The control group received laparoscopic cystectomy, and the observation group was treated with GnRHa plus lauromacrogol sclerotherapy. Curative effects were compared. Results: The total effective rate of the observation group (95.00%, 95% CI: 87.2–98.9) was higher than that of the control group (77.50%, 95% CI: 65.1–86.8; OR=5.51, 95% CI: 1.21–15.56, P < 0.05). After treatment, serum FSH, LH, E2, CA125, CA199 levels and VAS scores in the observation group were lower than those in the control group (all P < 0.05). The recurrence rate of the observation group (5.00%) was lower than that of the control group (17.